2273-PUB: Long-Term Incidence Rates of Complications in Patients with Type 2 Diabetes in Sweden

Abstract

While it is known that patients with type 2 diabetes mellitus (T2DM) are at an elevated risk of developing several complications, there are limited data on incidence of these diabetic complications based on extended follow-up time following diagnosis of T2DM. We conducted an observational database study among newly diagnosed T2DM patients using the National Diabetes and other registries in Sweden. We calculated the incidence rates (IR) for several diabetic complications as number of events per person years with 95% exact Poisson confidence intervals. A total of 100,878 persons with new diagnosis of T2DM were included; average age (SD) was 62.6 (12.5) years, and 42.7% was female. The mean follow-up time was 5.5 years with the maximum follow up of 17 years. The Figure below shows the cumulative incidence of different complications from time of diagnosis as well as the IR of these complications. The cumulative incidence for the different diabetic complications shows a steady increase over time. Disclosure A. Svensson: None. S. Franzén: None. R.M. Klok: Employee; Self; Merck & Co., Inc. Stock/Shareholder; Self; Merck & Co., Inc. T. Weiss: Employee; Self; Merck & Co., Inc. S. Rajpathak: Employee; Self; Menarini Group. B. Eliasson: Consultant; Self; Amgen, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Mundipharma International, Novo Nordisk A/S, Sanofi.